Join TherapeutAix at the SMR Meeting ‘Innovative New Pharma & Biotech Partnerships’
Darcey Black, Translational Director at TherapeutAix, will be co-organising and attending the ‘Innovative New Pharma and Biotech Partnerships: How is the landscape transforming?’ SMR Meeting taking place on 7th July 2022 at GSK Stevenage. The meeting will feature a panel; of experts from industry, CROs, medical charities and VCs who will share experiences and lessons […]
International NASH Day 2022 – Enabling therapies for patients
Non-alcoholic steatohepatitis, or NASH, remains a disease with no approved therapeutics. And it’s been a tough area for drug development, with numerous Phase 2b and Phase 3 failures in the last few years. As a result, the landscape of active development projects has changed quite a bit from the time our review on NASH was […]
TherapeutAix to present at Extracellular Matrix Pharmacology Congress
TherapeutAix is attending and presenting at the Extracellular Matrix Pharmacology Congress 2022, on 23-25 June at the Tivoli Congress Centre in Copenhagen. The congress will bring together experts from across the industry to discuss the extracellular matrix across organ diseases including liver, lung, kidney, skin, and immunology. Darcey Black (Director, Translational) will be presenting a […]
Strategy Workshop
The Challenge: TherapeutAix was contacted by an institution wanting to define areas to build capabilities. Their goal was to better complement expertise and to meet unmet demand for its partners and prospective clients. The Action: We aligned with our client on the scope of work. Next, we organised a workshop to align on must-haves as […]
Advancing Assets
The Challenge: TherapeutAix was approached by a small biotech company that operated in a fully virtual setting. To progress assets on a novel drug delivery platform technology, the biotech asked for help in defining the required steps to take the lead asset to IND-enabling studies and in the clinic. The Action: A thorough literature review […]
Workshops reloaded
At TherapeutAix, we have a number of tools to support our clients. In addition to, for example, the MIRIADD approach and our R&D network, we organise and moderate bespoke workshops for our clients. As workshops are a highly efficient and engaging means to work through scenarios and identify potential solutions, we are using them for […]
Rare and common diseases – where’s the link?
It’s Rare Disease Day. Last year on our blog, we looked at how rare diseases can help better our understanding of common diseases. This year, we delve into whether the reverse can be true as well. What is a rare disease? In the European Union, a disease is categorised as ‘rare’ if it affects fewer […]
Adoption and cost-effectiveness of IPF therapies
Fibrotic remodelling occurs in many diseases. Thinking about idiopathic pulmonary fibrosis (IPF) as a ‘purely’ fibrotic condition, with currently unknown aetiology, may offer strategic insights into IPF drug development that are similarly applicable to other indications. In this blog we look at the adoption and cost-effectiveness of two approved IPF therapies, nintedanib and pirfenidone, and […]
Happy Birthday TherapeutAix! Celebrating our third year
As TherapeutAix celebrates our three-year birthday this month, we thought it would be a great opportunity to take a look back at our achievements over the last year and share some of our top highlights, including events we’ve hosted and attended, projects we’ve worked on, and our latest publications. Welcoming new partners Following a fruitful […]
COVID-19 and Learning about Lung Fibrosis
Emerging understanding of the clinical course of COVID-19 may enable a better understanding of fibrosis in the lung. Future learnings may eventually be applicable to IPF and require new approaches to drug development. Reversing fibrosis and restoring lung function has been an aspiration for the treatment of patients with interstitial lung disease (ILD) but the […]